Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase IIa trial of ZP 4207 for treatment of hypoglycemia

Trial Profile

Second phase IIa trial of ZP 4207 for treatment of hypoglycemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Dasiglucagon (Primary)
  • Indications Hypoglycaemia; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2017 New trial record
    • 17 May 2017 According to Zealand Pharma media release, results from this trial are expected in Q2 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top